Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Pediatrix Medical Group director-linked trust sells shares
A trust associated with director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group common stock in an open-market transaction at a weighted average price of $23.75 per share, with individual trade prices ranging from $23.55 to $23.85.
The shares were held by The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees and members of her immediate family are beneficiaries. Following the sale, the trust reported no remaining Pediatrix shares, while Weis directly holds 18,623 shares.
Pediatrix Medical Group director Thomas McEachin reported charitable-style transfers of company stock. On May 13, 2026, he made bona fide gifts totaling 22,854 shares of Pediatrix common stock. One 11,427-share gift involved a trust where he and his spouse serve as trustees and beneficiaries, and another 11,427-share gift involved directly held shares.
After these transactions, McEachin reports indirect ownership of 66,073 shares through the trust and continued direct ownership of 7,196 shares. These are non-cash, gift transfers rather than open-market sales or purchases, and do not change his role as a director.
Pediatrix Medical Group, Inc. submitted a Form 144 notice via Robert W. Baird & Co. proposing the resale of restricted common shares tied to compensatory vesting.
The excerpt lists proposed shares associated with four vesting dates: 07/12/2021 (2,926 shares), 07/12/2023 (3,777), 05/11/2024 (10,965), and 05/09/2025 (18,360); aggregate appears as 36,028 shares.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported a gift transfer of company stock. On May 11, 2026 she made a bona fide gift of 40,826 shares of Pediatrix common stock to a family trust where she and her spouse serve as trustees and her immediate family members are beneficiaries. Following these transactions, she reports 108,410 shares held directly and 93,424 shares held indirectly through a trust. Moore disclaims beneficial interest in the trust-held shares except to the extent of her pecuniary interest.
Rucker Michael A. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Michael A. Rucker received a grant of 7,196 shares of common stock as an equity award. The restricted shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Rucker directly holds 66,297 shares of Pediatrix Medical Group common stock.
Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Laura A. Linynsky received a grant of 7,196 shares of restricted common stock as an annual equity award. The grant was made at no cash cost per share under the company’s Amended and Restated 2008 Incentive Compensation Plan. These restricted shares are scheduled to vest on May 7, 2027, meaning they become fully owned if service conditions are met. Following this award, Linynsky directly holds a total of 39,428 shares of Pediatrix Medical Group common stock.
SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Guy P. Sansone received a grant of 7,196 shares of restricted common stock as an annual equity award. The shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock, reflecting routine stock-based compensation rather than an open-market purchase or sale.
Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Sylvia Jean Young reported an equity award of common stock. She received 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock on May 7, 2026, as a grant under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
The restricted shares were granted at no cash cost to her and will vest on May 7, 2027, subject to the plan’s terms. After this award, she now directly holds 47,814 shares of Pediatrix common stock, reflecting her ongoing equity-based compensation and alignment with shareholders.
Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director John M. Starcher Jr. received an equity grant of 7,196 shares of common stock as a compensation award. The shares were granted at no cash cost to him and increase his direct holdings to 73,260 shares.
These are restricted shares granted under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with an annual equity award. The restricted stock is scheduled to fully vest on May 7, 2027, meaning the shares become unrestricted for him on that date if vesting conditions are satisfied.
Weis Shirley A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Shirley A. Weis received 7,196 restricted shares of common stock as an equity grant. The award was made at a price of $0.00 per share under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
These restricted shares are scheduled to vest on May 7, 2027. Following the grant, Weis directly holds 18,623 common shares and is also reported as an indirect owner of 36,028 common shares held by The Weis Family Trust, for which she and her husband serve as trustees and her immediate family members are beneficiaries.